We have read with great interest the recent comment by Dr Dauby considering
cardiovascular side effects of remdesivir [1] that might call into question its role in the …

Purpose Remdesivir is the first line hospital treatment of the SARS-CoV-2 infection. Despite
its widespread use during COVID-19 pandemic, a limited number of data, also conflicting …

Background Despite increasing concerns about the association between remdesivir and
bradycardia in severe coronavirus disease 2019 (COVID-19) patients receiving remdesivir …

Remdesivir is the only antiviral drug currently approved for the treatment of severe COVID-
19. It was recently observed that use of remdesivir might be associated with higher …

To the Editor, Coronavirus disease 2019 (COVID‐19) is still a global concern with elevated
morbidity and mortality. 1–3 Several drugs were evaluated, but, until now, only remdesivir …

We read with interest the systematic review and meta-analysis by Lee et al.[1] concerning
the use of remdesivir for the treatment of patients with coronavirus disease 2019. The …

Remdesivir treatment and transient bradycardia in patients with coronavirus diseases 2019 (COVID-19)
- PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage …

We thank Beccacece et al. for their letter to the editor notifying that a study that we included
in our recent meta-analysis has since been retracted. We believe that it is paramount to …

Remdesivir has been recently recognized as a benefi-cial antiviral therapy for the treatment
of hospitalized patients with coronavirus disease 2019 (COVID-19) with lower respiratory …

Abstract The coronavirus disease 2019 (COVID-19) pandemic has been an enormous
public health challenge. The pursuit for an effective therapy led to the use of the antiviral …